Clinical and Functional Outcome Comparison for Platelet-Rich Plasma with Steroid Injection in Patients with Isolated SubAcromial Impingement Syndrome

Atul Mahajan
Department of Orthopedics, Lady Hardinge Medical College, New Delhi, India

Abstract

Objective: The objective of this study is to compare the 6-weeks, 3-, and 6-month outcome in 80 patients who received an injection of platelet-rich plasma (PRP) or steroid for subacromial impingement syndrome (SIS). Materials and Methods: Forty-two males and 38 females received a single-dose injection of PRP (n = 40) or steroid (n = 40) for SIS that had not responded to conservative treatment for more than 6 months. Both groups were put on physiotherapy protocol followed in our institution. The use of nonsteroid anti-inflammatory drugs was prohibited. Patients were evaluated before and 6 weeks, 3 and 6 months after treatment using the constant score, visual analog scale (VAS) for pain, and range of motion (ROM) of the shoulder. Results: No local or systemic complication occurred. Improvement in the Constant score and VAS for pain at 6 weeks, 3-, and 6-months was clinically better following steroid than PRP injection. However, this difference was statistically insignificant. The two groups were comparable for improvement in ROM of the shoulder. Conclusion: PRP injection was not more effective than steroid injection for the treatment of SIS in terms of at the end of 6 months. However, long-term studies should be indicated to substantiate the findings.

Keywords: Constant score, platelet-rich plasma, subacromial impingement syndrome, visual analog scale

INTRODUCTION

Subacromial impingement syndrome (SIS) is one of the most common causes of shoulder pain in adults and is characterized by painful functional limitation of the shoulder, especially with overhead activities. There occurs soft-tissue impingement between the coracoacromial arch and greater tuberosity of the humeral head, which produces subacromial bursitis, rotator cuff tendinitis, and rotator cuff tears. SIS without a rotator cuff tear can generally be treated with conservative treatment, including medication with nonsteroidal anti-inflammatory drugs (NSAIDs), pain killers, physical therapy, and local corticosteroid injection. A local corticosteroid injection is used widely for relieving chronic pain in orthopedic lesions, due to its strong anti-inflammatory and analgesic effects. Nevertheless, there is some concern regarding its side effects when used around a tendon lesion. Today, orthobiologics are commonly used in many orthopedic applications, especially in the treatment of tendinopathies.[1] Platelet products represent an enriched autologous source of platelets, which contain granules filled with growth factors, delivering high concentrations of growth factors above physiological levels.[2] There is some clinical evidence that the application of autologous platelets may help to revascularize the area of injury, to promote tendon healing, and to improve pain and functional outcomes in rotator cuff pathologies.[3,4] This study compared the 6-week, 3-, and 6-months outcome in 80 patients who received a single-dose injection of platelet-rich plasma (PRP) or steroid for SIS.

MATERIALS AND METHODS

Eighty-three consecutive patients seen by the author in the outpatient department between 2014 and 2016 were enrolled

Address for correspondence: Dr. Atul Mahajan,
Department of Orthopedics, Lady Hardinge Medical College, New Delhi, India.
E-mail: dratulmahajan84@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Mahajan A. Clinical and functional outcome comparison for platelet-rich plasma with steroid injection in patients with isolated subacromial impingement syndrome. J Orthop Traumatol Rehabil 2019;11:79-83.

Submission: 24.06.2017 Acceptance: 14.09.2019
Web Publication: 24.03.2020

© 2020 Journal of Orthopaedics, Traumatology and Rehabilitation | Published by Wolters Kluwer - Medknow
in this study. Patients were included if they were ≥18 years. The diagnosis of SIS was made based on a history of shoulder pain with overhead activities and clinical signs of impingement (either in internal rotation or external rotation). Exclusion criteria were generalized inflammatory arthritis, including ankylosing spondylitis, rheumatoid arthritis or psoriatic arthritis, prior supraspinatus tendon tear, pregnancy, severe infection, known malignancy, bleeding disorder, nerve-related symptoms such as radiculopathy or osteoarthritis of the shoulder, previous extracorporeal shock wave therapy or prior injections into the shoulder immunodeficiency, the use of anticoagulants, the use of NSAIDs in 5 days before and during the treatment and hemoglobin value <11 g/dl, and platelet value <150,000 mm$^3$. Exclusions were made based on history and clinical examinations performed by the author in combination with the results of shoulder radiographs and ultrasounds performed if deemed necessary. Anteroposterior radiographic images were taken in a neutral as well as a 90° abduction position.

All injections were performed by the author. Blind injections were performed with the patient in the same upright sitting position. A posterior approach was used, and the needle was inserted 1 cm medially and inferiorly to the posterior lateral corner of the acromion and directed cephalad, anteriorly, and medially toward the subacromial bursa. The first consecutive 40 patients received a cortisone injection. The injection fluid contained 1 mL of 40 mg/mL methylprednisolone acetate and 5 mL of 1% lidocaine hydrochloride. The PRP was prepared manually using single spin rotation.$^{[5,6]}$ A total of 30 cc peripheral blood was drawn from the antebrachial region into tubes containing 3.2% sodium citrate. The tubes were centrifuged at 1800 rpm for 8 min at room temperature. From the 3.5 mL PRP, 1 mL was sent to the laboratory for bacteriological testing and platelet count; the platelet count was four times greater than the thrombocyte count in the peripheral blood. The 2.5 mL PRP was activated by 5.5% calcium chloride (50 μL in 1 mL PRP), calcium chloride was added to the PRP concentrate to activate the platelets for inducing the rapid formation of the fibrin clot. The patients were kept in observation in lying down position for 30 min following injections. Both groups were instructed to perform standard rotator cuff stretching and strengthening exercises started 3 weeks after the injection but were advised to avoid sport and strenuous activities for 6 weeks. NSAIDs were not allowed for 6 months.

**Clinical outcomes**

After 6 weeks, 12 weeks, and 6 months, patients were examined in the outpatient clinic. The main outcome measure was pain with overhead activities using a visual analog scale (VAS). A 10 cm line with “no pain” at one end and “the worst imaginable pain” at the other end was marked by the patient, and the distance from the no pain end was converted to a score of 100 (1 mm = 1 point). This was assessed at baseline and again at 6 weeks, 3-, and 6-month follow-up.

We used Constant Score (CS)$^{[7]}$ which was among the first shoulder score systems developed and is considered the most commonly used scoring system for the evaluation of various disorders of the shoulder.$^{[7]}$ The CS assesses subjective and objective shoulder function with respect to: (A) pain; (B) activities of daily living; (C) range of motion (ROM); and (D) strength. The CS is often used to evaluate treatment progress and to compare the results of clinical trials for several specific shoulder disorders.$^{[8,9]}$ The European Society for Surgery of the Shoulder and Elbow and the Journal of Shoulder and Elbow Surgery recommend the CS for use in research on shoulder disorders.$^{[8,9]}$

The author also assessed passive shoulder ROM in forward flexion, extension, abduction, external rotation, and internal rotation. During the course of the study, the patients were restricted from the use of any analgesic or anti-inflammatory medication or other treatments.

Patient characteristics and outcome measures in the two groups were compared using the Chi-square test and Student’s $t$-test. A value of $P < 0.05$ was considered statistically significant.

**Results**

There were 83 patients who met the inclusion criteria for the study. Three were lost to follow-up after receiving the injection. Therefore, 80 patients were alternatively allocated either the PRP group (40 shoulders) or the STR group (40 shoulders).

The final population [Table 1] comprised 42 men (PRP group = 22; STR group = 20) and 38 women (PRP group = 18; STR group = 20) with a mean age of 56.35 ± 6.58 years (PRP group = 57.65 ± 5.43; STR group = 55.05 ± 5.93). The mean body mass index was 25.71 ± 3.26 kg/m$^2$ (PRP group = 26.19 ± 3.75; STR group = 25.24 ± 2.77). The mean duration of symptoms was 9 months (PRP = 8.65 ± 2.44; STR = 9.7 ± 1.47).

Seventeen injections into the right shoulder and 23 into the left shoulder were performed in the PRP group and 21 injections into the right shoulder and 19 into the left shoulder in the STR group. No infection was observed after injection in both groups. The study group had 66% ($n = 61$) patients who had sedentary lifestyle compared to 24% ($n = 19$) patients who were involved in heavy manual occupation. Majority of the patients were right-hand dominant (90%).

**Table 1: Demographic factors of different groups. There were no significant differences between the groups**

| Variables                  | PRP   | Steroid |
|----------------------------|-------|---------|
| Number of patients         | 40    | 40      |
| Age                        | 57.65±5.43 | 55.05±5.93 |
| Gender ratio (female/male) | 18/22 | 20/20   |
| BMI                        | 26.19±3.75 | 25.24±2.77 |
| Duration                   | 8.65±2.44  | 9.7±1.47 |
| Dominance ratio (R/L)      | 40/0   | 32/8    |
| Lifestyle (sedentary/phys) | 33/7   | 28/12   |
| BMI: Body mass index       |        |         |
While VAS in overhead activities at the end of treatment was clinically higher in the STR group than the PRP group, this clinically significant difference was found to be statistically insignificant ($P > 0.05$) [Table 2].

Comparison of Constant Score (CS) in both the groups over a period of followup showed that STR group had clinically significant but statistically insignificant difference ($P > 0.05$) from PRP group.

When we compared the PRP and STR groups [Table 3], there was no significant difference between the groups for the flexion degree of the shoulder before treatment, the increase of the flexion degree at the end of the treatment and at the 6th month after the treatment was similar in both the groups ($P > 0.05$).

While before the treatment the extension degree of the shoulder was significantly higher in the STR group than the PRP group, at the 6th month after the treatment the extension degree of the shoulder was statistically insignificant in both the groups ($P > 0.05$).

The abduction degree of the shoulder was significantly higher in the PRP group than the STR group before the treatment ($P < 0.05$). Postinjection, at all the evaluation steps, there was no significant difference between the groups for the abduction degree of the shoulder ($P > 0.05$).

After 6 months, the external rotation degree of the shoulder was significantly higher in the STR group than the PRP group, whereas the internal rotation degrees of the shoulder at all the evaluation steps were similar in both the groups ($P > 0.05$).

The syndrome is conventionally divided into three stages:[10] Stage I, edema and hemorrhage; Stage II, fibrosis and tendinitis; and Stage III, tears of the rotator cuff, bicep ruptures, and bone changes. The condition usually begins gradually, and then over time becomes continuous.

The first mode of treatment is nonoperative, involving rest, subacromial corticosteroid injections, 19 oral nonsteroidal anti-inflammatory drugs, and physiotherapy.[12] Although surgical treatment has not been conclusively shown to be superior to conservative treatment, arthroscopic acromioplasty is still a popular procedure with a rising incidence over the last decade.[13,14] It is generally agreed that a period of rehabilitation and physical therapy is advisable for shoulder impingement syndrome, whereas failure to respond to sustained conservative management and continuing severe shoulder pain with functional restriction are indications for surgery.[13,14]

### Table 2: Visual analog scale and constant score outcomes of platelet-rich plasma and steroid groups

| VAS          | PRP          | STR          | $P^b$ |
|--------------|--------------|--------------|-------|
| Preoperator  | 68.15±11.97  | 69.2±11.05   | NS    |
| 6 weeks      | 40.85±10.89  | 39.1±7.32    | NS    |
| 3 months     | 33.2±7.09    | 34.65±5.1    | NS    |
| 6 months     | 28.5±6.34    | 30.6±6.61    | NS    |
| $P^a$        | <0.05        | <0.05        |       |

$^a$Significant difference comparison between PRP and STR groups,

$^b$Significant difference comparison between preoperative and final follow-up values. VAS: Visual analog scale, PRP: Platelet-rich plasma group, STR: Steroid group, NS: Not significant

### Table 3: Range of motion score outcomes of platelet-rich plasma and steroid groups

| Flexion          | PRP          | STR          | $P^b$ |
|------------------|--------------|--------------|-------|
| Preoperator      | 118±16.04    | 117.25±18.22 | NS    |
| 6 weeks          | 142.75±9.4   | 140.5±11.2   | NS    |
| 3 months         | 152.5±7.93   | 152.75±8.98  | NS    |
| 6 months         | 167±7.58     | 168±5.86     | NS    |
| $P^a$            | <0.05        | <0.05        |       |

| ABD              | PRP          | STR          | $P^b$ |
|------------------|--------------|--------------|-------|
| Preoperator      | 95±15.44     | 88.75±15.43  | <0.05 |
| 6 weeks          | 122±9.66     | 121±10.33    | NS    |
| 3 months         | 141±9.28     | 140±9.34     | NS    |
| 6 months         | 157.25±7.59  | 158.5±8.18   | NS    |
| $P^a$            | <0.05        | <0.05        |       |

| IR               | PRP          | STR          | $P^b$ |
|------------------|--------------|--------------|-------|
| Preoperator      | 55.5±5.29    | 54.25±4.61   | NS    |
| 6 weeks          | 67.25±5.18   | 65.75±5.38   | NS    |
| 3 months         | 72.75±4.38   | 72.25±4.66   | NS    |
| 6 months         | 80±6.41      | 80.25±7.76   | NS    |
| $P^a$            | <0.05        | <0.05        |       |

| ER               | PRP          | STR          | $P^b$ |
|------------------|--------------|--------------|-------|
| Preoperator      | 52.75±6.3    | 52±7.23      | NS    |
| 6 weeks          | 65.76±7.66   | 65.5±6.58    | NS    |
| 3 months         | 70.5±5.97    | 74.5±4.78    | <0.05 |
| 6 months         | 77.75±5.42   | 81±5.45      | <0.05 |
| $P^a$            | <0.05        | <0.05        |       |

$^a$Significant difference comparison between PRP and STR groups,

$^b$Significant difference comparison between preoperative and final follow-up values. ABD: Abduction, IR: Internal Rotation, ER: External Rotation, PRP: Platelet-rich plasma group, STR: Steroid group, NS: Not significant

### Discussion

SIS was first introduced by Neer and described as “crepitus and tenderness over the supraspinatus tendon, a good range of assisted motion but a painful arc of active elevation from 70 to 120 and pain at the anterior edge of the acromion on forced elevation.”[10]

Hawkins described pain provocation on internal rotation in forward flexion and attributed this sign to Hawkins and Kennedy.[11] The maneuver has also been described in a more abducted position. Jobe described weakness on resisted elevation from 90 onward with the arm in internal rotation. The diagnosis of SIS is based on patient history, clinical examination, and radiological finding.

The syndrome is conventionally divided into three stages:[10] Stage I, edema and hemorrhage; Stage II, fibrosis and tendinitis; and Stage III, tears of the rotator cuff, bicep ruptures, and bone changes. The condition usually begins gradually, and then over time becomes continuous.
In an early study, collagen necrosis was reported after directly injecting hydrocortisone in rabbit calcaneal tendons. Another study reported the relationship between local corticosteroid injection and tendon rupture. Subacromial corticosteroid injection in impingement syndrome is safe; but several studies reported that repeated steroid injections may result in damage to the rotator cuff tendon.

Steroid injection is active for up to 6 months and is more efficient than NSAID, but it may result in complications such as skin depigmentation, fat atrophy, or tendon ruptures.

In patients with SIS, pain and limitation in ROM are common. The subacromial bursa between the acromion and the humeral head is a source of pain, as it has mechanoreceptors and a large number of pathological nerve endings that are associated with clinical symptoms. The increased amount of substance-P and vascular endothelial growth factor in the subacromial bursa is associated with pain.

Numerous studies have documented the beneficial effects of individual growth factors on tendon healing shown for platelet concentrates and other orthobiologics such as autologous processed serum contain factors such as bone morphogenetic proteins, transforming growth factors, and fibroblast growth factors. Application of these agents was shown to promote tendon cell proliferation, collagen synthesis, and vascularization in vitro and in vivo. A beneficial effect was also seen using PRP, platelet-leukocyte membrane, platelet-rich fibrin matrix or plasma rich in growth factors in addition to rotator cuff tear surgery.

A platelet count over 300,000/μl in PRP is considered effective. A platelet concentration 2.5 times greater than the basal platelet count is reported to be the most effective. The PRP is activated by adding bovine or human thrombin or calcium chloride. Growth factors and cytokines are revealed with the formation of platelet gel from the activated PRP. However, studies warning of hyperplasia, carcinogenesis, or tumor growth secondary to PRP injection are limited.

Hence, orthobiologics such as PRP, platelet-poor plasma, and autologous processed serum could be an option for the treatment of this pathology. To the best of our knowledge, the effect of PRP injections on shoulders with isolated SIS as compared to standard injection therapy with cortisone has not had many studies. Therefore, this study evaluated PRP injections versus cortisone injections into the subacromial space in patients without partial tears of the supraspinatus tendon as confirmed by clinical examination and ultrasonographic findings. The results should contribute to a better understanding of the role of PRP in treatment of symptomatic SIS. Before admission, all patients reduced their activities of daily living or suspended their sport activities due to their shoulder pain.

The most important findings of the present study were better scores and clinical improvement after injection at different follow-up periods in the STR group in comparison with the PRP group. However, statistically significant differences between the two groups in terms of shoulder function and scores could not be found except for ER improvement which was more in STR group compared to PRP group ($P < 0.05$).

Both groups showed a statistically significant better shoulder function after sub-acromial injection over time compared to pre-injection values. Cortisone is widely used to treat patients with shoulder pain, and there is no doubt about the positive effect on pain especially in the short term. However, the potential complications of corticosteroid injections should also be taken into account, especially for the elderly.

After the injection, both the groups had decreased pain with overhead activities in the VAS score that was clinically relevant as well as a significant improvement in CSs. The decrease in pain on the VAS and increase in function on the CS were not significantly different between groups, suggesting that there was no added clinical benefit in pain reduction or improved function of PRP injection compared to steroid injection.

The rather clear results of this study may because the author was involved in assessing all the patients clinically and the shoulder scores, that the number of patients included in this study was reasonably high and that the clinical examinations by means of shoulder scoring systems and injection protocols were strictly standardized.

**Conclusion**

PRP injection was not more effective than steroid injection for the treatment of SIS in terms of at the end of 6 months. However, long-term studies should be indicated to substantiate the findings.

**Limitation**

A weakness of this study is the relatively short-term follow-up of 6 months. A longer follow-up of at least 12 months may have led to differences in outcomes between groups that may not have been apparent in the short term. We did not assess the accuracy of injections using MRI, and perhaps, the fact that all the injections were performed by an experienced orthopaedic surgeon well versed in injection techniques may have resulted in all injections accurately placed in the subacromial bursa, therefore diminishing the differences in the treatment of both groups, leading to the similarity of outcomes. The study is in reference to subacromial injections only, and these results cannot be extrapolated to injections in the glenohumeral joint. We tried to ensure that the study was conducted on patients with consistent homogeneous impingement with the absence of other pathological conditions; however, in some of the cases, the cause of pain changed or evolved over time.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.
REFERENCES
1. Dhillon MS, Behera P, Patel S, Shetty V. Orthobiologics and platelet rich plasma. Indian J Orthop 2014;48:1-9.
2. Rutgers M, Saris DB, Dhert WJ, Creemers LB. Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection. Arthritis Res Ther 2010;12:R114.
3. Randelli P, Arrigoni P, Ragone V, Akiprandi A, Cabitza P. Platelet rich plasma in arthroscopic rotator cuff repair: A prospective RCT study, 2-year follow-up. J Shoulder Elbow Surg 2011;20:518-28.
4. Peerbooms JC, Sluimer J, Bruin CJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: Platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med 2010;38:255-62.
5. Anitua E. Plasma rich in growth factors: Preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 1999;14:529-35.
6. Anitua E, Andia I, Ardanaz B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004;91:4-15.
7. Constant CR, Gerber C, Emery RJ, Sojbjerg JO, Gohlke F, Boileau P, et al. A review of the constant score: Modifications and guidelines for its use. J Shoulder Elbow Surg 2008;17:355-61.
8. Iannotti JP, Bernot MP, Kuhlman JR, Kelley MJ, Williams GR. Postoperative assessment of shoulder function: A prospective study of its use. J Shoulder Elbow Surg 1996;5:449-57.
9. Wright RW, Baumgarten KM. Shoulder outcomes measures. J Am Acad Orthop Surg 2010;18:436-44.
10. Hawkins RJ, Kennedy JC. Impingement syndrome in athletes. Am J Sports Med 1980;8:151-8.
11. Impingement lesions. Neer CS Clin Orthop Relat Res 1983;(173):70-7.
12. Morrison DS, Frogameni AD, Woodworth P. Non-operative treatment of impingement lesions. Neer CS Clin Orthop Relat Res 1983;(173):70-7.
13. Macefield RC, Boulind CE, Blazeby JM. Selecting and measuring optimal outcomes for randomised controlled trials in surgery. Langenbecks Arch Surg 2014;399:263-72.
14. Mitchell C, Adebajo A, Hay E, Carr A. Shoulder pain: Diagnosis and management in primary care. BMJ 2005;331:1124-8.
15. Salter RB, Gross A, Hall JH. Hydrocortisone arthropathy – An experimental investigation. Can Med Assoc J 1967;97:374-7.
16. Tsai WC, Tang FT, Wong MK, Pang JH. Inhibition of tendon cell migration by dexamethasone is correlated with reduced alpha-smooth muscle actin gene expression: A potential mechanism of delayed tendon healing. J Orthop Res 2003;21:265-71.
17. Unverferth LJ, Olix ML. The effect of local steroid injections on tendon. J Sports Med 1973;1:31-7.
18. Tomita Y, Ozaki J, Sakurai G, Kondo T, Nakagaki K, Tamai S. Neurohistory of the subacromial bursa in rotator cuff tear. J Orthop Sci 2007;2:295-300.
19. Yanagisawa K, Hamada K, Gotoh M, Tokunaga T, Oshika Y, Tomisawa M, et al. Vascular endothelial growth factor expression in the subacromial bursa is increased in patients with impingement syndrome. J Orthop Res 2001;19:448-55.
20. Sakai H, Fujita K, Sakai Y, Mizuno K. Immunolocalization of cytokines and growth factors in subacromial bursa of rotator cuff tear patients. Kobe J Med Sci 2001;47:25-34.
21. Cervellin M, de Girolamo L, Bait C, Denti M, Volpi P. Autologous platelet-rich plasma gel to reduce donor-site morbidity after patellar tendon graft harvesting for anterior cruciate ligament reconstruction: A randomized, controlled clinical study. Knee Surg Sports Traumatol Arthrosc 2012;20:114-20.
22. Creaney L, Hamilton B. Growth factor delivery methods in the management of sports injuries: The state of play. Br J Sports Med 2008;42:314-20.
23. de Mos M, van der Windt AE, Jahn H, van Schie HT, Weins H, Verhaar JA, et al. Can platelet-rich plasma enhance tendon repair? A cell culture study. Am J Sports Med 2008;36:1171-8.
24. Fluckiger R, Evans CH, Majewski M. Effect of BMP-12, TGF-β1 and autologous conditioned serum on growth factor expression in achilles tendon healing. Knee Surg Sports Traumatol Arthrosc 2012;20:1907-14.
25. Everts PA, Devilee RJ, Brown Mahoney C, van Erp A, Oosterbos CJ, de Mos M, van der Windt AE, Jahr H, van Schie HT, Weinans H, Verhaar JA, et al. Can platelet-rich plasma enhance tendon repair? A cell culture study. Am J Sports Med 2008;36:1171-8.
26. Creaney L, Hamilton B. Growth factor delivery methods in the management of sports injuries: The state of play. Br J Sports Med 2008;42:314-20.
27. A randomized, controlled clinical study. Knee Surg Sports Traumatol Arthrosc 2012;20:1907-14.
28. Peppeley WL, Eppley BL. Platelet rich plasma: Biology and new technology. J Craniomaxillofac Surg 2005;16:1043-54.